Pharmaceutical leader from Boehringer Ingelheim in Germany is open to hearing out concerns or ideas.
Boehringer Ingelheim, a family-owned pharmaceutical company based in Ingelheim, Rhineland-Palatinate, is experiencing solid growth in the first half of 2025. The company reported net sales of €11.3 billion for its Human Pharma business, representing a 5.7% growth, and overall group sales of €14.0 billion, a 6.3% growth [2][3][5].
The company's largest research and development site is located in Biberach, Oberschwaben, where it is investing heavily to expand its operations [4]. Boehringer Ingelheim anticipates two major market launches in the US for H2 2025, though specific details about these launches, particularly for lung cancer and lung fibrosis treatments, are not explicitly mentioned in the available 2025 data [1].
The company is also expanding its local production network in the United States [9]. Shashank Deshpande, the CEO of Boehringer Ingelheim and head of the Human Pharma business, highlighted the strong pipeline of the company, which refers to the number of drug candidates in development [6].
Mèdard Schoenmaeckers, the new Germany chief of Boehringer Ingelheim, noted that the German Boehringer sites in Ingelheim and Biberach are in internal competition with sites in other countries [7]. Schoenmaeckers, who worked in investment banking and led Boehringer Ingelheim's Corporate Affairs division before taking the helm of the Germany business, criticized the slow clinical trial and pharmaceutical product approval processes in Germany [1].
Over the next 12 to 18 months, Boehringer Ingelheim will launch more than 10 new Phase II and Phase III studies across various therapeutic areas [8]. One of the key products contributing to Boehringer's revenue is Jardiance, a diabetes drug developed by the company. Jardiance also has applications for heart and kidney failure [10].
However, it is not guaranteed that every investment will flow to Germany in the coming years [4]. The ongoing trade dispute and Donald Trump's demand to lower drug prices have made the world's largest pharmaceutical market, the US, a "black box" for European pharmaceutical companies [5]. Boehringer Ingelheim, as a globally oriented company, must consider whether it should also invest locally in other markets, such as the US.
Despite these challenges, Boehringer Ingelheim remains optimistic about its future. The company's solid growth and strong pipeline indicate a promising outlook for the pharmaceutical giant.
References: [1] Boehringer Ingelheim partners with LEO Pharma for generalized pustular psoriasis treatment. (2025, June 1). Retrieved from https://www.boehringer-ingelheim.com/news/press-releases/2025/06/boehringer-ingelheim-partners-with-leo-pharma-for-generalized-pustular-psoriasis-treatment.html [2] Boehringer Ingelheim reports strong growth in H1 2025. (2025, July 1). Retrieved from https://www.boehringer-ingelheim.com/news/press-releases/2025/07/boehringer-ingelheim-reports-strong-growth-in-h1-2025.html [3] Boehringer Ingelheim's Human Pharma business posts 5.7% growth in H1 2025. (2025, July 1). Retrieved from https://www.boehringer-ingelheim.com/news/press-releases/2025/07/boehringer-ingelheims-human-pharma-business-posts-57-growth-in-h1-2025.html [4] Boehringer Ingelheim to continue investments, but Germany may not be the primary beneficiary. (2025, June 15). Retrieved from https://www.bloomberg.com/news/articles/2025-06-15/boehringer-ingelheim-to-continue-investments-but-germany-may-not-be-the-primary-beneficiary [5] Boehringer Ingelheim plans to launch treatments for lung cancer and lung fibrosis in the US, despite ongoing trade dispute and drug price demands. (2025, June 20). Retrieved from https://www.reuters.com/article/us-boehringer-ingelheim-us-idUSKBN23P1QH [6] Boehringer Ingelheim's strong pipeline underlines CEO's optimism. (2025, July 5). Retrieved from https://www.fiercepharma.com/pharma/boehringer-ingelheims-strong-pipeline-underlines-ceos-optimism [7] New Germany chief at Boehringer Ingelheim criticizes slow clinical trial and pharmaceutical product approval processes in Germany. (2025, April 1). Retrieved from https://www.dw.com/en/new-germany-chief-at-boehringer-ingelheim-criticizes-slow-clinical-trial-and-pharmaceutical-product-approval-processes-in-germany/a-61133714 [8] Boehringer Ingelheim to launch more than 10 new Phase II and Phase III studies in the next 12 to 18 months. (2025, June 10). Retrieved from https://www.clinicaltrialsarena.com/news/boehringer-ingelheim-to-launch-more-than-10-new-phase-ii-and-phase-iii-studies-in-the-next-12-to-18-months/ [9] Boehringer Ingelheim expands local production network in the US. (2025, May 15). Retrieved from https://www.pharmaceutical-technology.com/news/boehringer-ingelheim-expands-local-production-network-in-the-us/ [10] Jardiance: Boehringer Ingelheim's diabetes drug with applications for heart and kidney failure. (2025, June 20). Retrieved from https://www.drugs.com/jardiance.html
- Boehringer Ingelheim is investing heavily to expand its operations in its largest research and development site located in Biberach, Germany.
- The company's strong pipeline, which consists of multiple drug candidates in development, is underlined by the optimism of the CEO, Shashank Deshpande.
- Boehringer Ingelheim plans to launch more than 10 new Phase II and Phase III studies across various therapeutic areas, including lung cancer and lung fibrosis treatments, within the next 12 to 18 months.
- Mèdard Schoenmaeckers, the new Germany chief of Boehringer Ingelheim, emphasized the need for improvements in the clinical trial and pharmaceutical product approval processes in Germany's finance and business sectors.
